Commonwealth of Pennsylvania Public School Empls Retrmt SYS Makes New $447,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 7,165 shares of the company’s stock, valued at approximately $447,000.

A number of other institutional investors have also made changes to their positions in the business. Arizona State Retirement System lifted its holdings in TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock worth $603,000 after buying an additional 184 shares in the last quarter. National Bank of Canada FI lifted its stake in shares of TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the period. Quarry LP boosted its holdings in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in TransMedics Group by 7.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company’s stock valued at $294,000 after acquiring an additional 317 shares during the last quarter. Finally, Park Avenue Securities LLC increased its position in TransMedics Group by 3.8% in the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock worth $548,000 after purchasing an additional 322 shares during the period. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

TMDX stock opened at $70.44 on Friday. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.37 billion, a PE ratio of 74.94 and a beta of 2.12. The business’s 50-day moving average price is $68.88 and its two-hundred day moving average price is $88.90.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird reduced their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.